Extended use of oral anticoagulant after hospital discharge reduces non-fatal blood clots
The use of an oral anticoagulant medicine in medically ill patients for 45 days following their discharge from the hospital reduces the rate of non-fatal symptomatic blood clots with no impact on fatal blood clots, according to late breaking results from the MARINER trial presented today in a Hot Line Session at ESC Congress 20181 and published in The New England Journal of Medicine.
Professor Alex Spyropoulos, study author, of the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, US, said: “Anticoagulants help prevent blood clots in medically ill patients while they are under our supervision at the hospital. However, the risk of blood clots extends well beyond this period. Our results suggest we may be able to offer further protection to patients at risk from non-fatal blood clots, with no increase in major bleeding, by prescribing an oral anticoagulant for use after discharge. This study has potential to reduce the public healthcare burden of non-fatal blood clots in a large proportion of medically ill patients.”
Each year, around 20 million acutely ill medical patients are hospitalised in the US and EU with conditions such as heart attack, pneumonia, flu, bronchitis, asthma, or broken bones. A significant proportion of these patients are at risk of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, while in hospital and up to six weeks afterwards. Around 70% of hospital-acquired fatal pulmonary embolism occurs in medically ill patients.
Anticoagulants delivered by intravenous drip or injection are recommended to prevent blood clots (called thromboprophylaxis) in medically ill patients while in hospital, but guidelines do not recommend any use of anticoagulants post-discharge. However, after leaving the hospital the rate of symptomatic VTE more than doubles over the first 21 days and is associated with a five-fold increased risk of fatal pulmonary embolism within 30 days post-discharge.
The MARINER trial2 investigated whether continuing thromboprophylaxis with an oral anticoagulant after discharge could reduce the risk of symptomatic VTE and VTE-related death in medically ill patients at risk for VTE. The trial enrolled 12,024 patients from 671 centres in 36 countries. Patients were 40 years of age or older, had been hospitalised for an acute medical illness, and had other risk factors for VTE as defined by a VTE risk score that included immobilisation for one day or longer, being in intensive care, age over 60 years, limb paralysis, previous VTE, thrombophilia or a D-dimer level more than two times the upper limit of normal.
Patients were randomly allocated to a 45-day course of either once daily oral rivaroxaban 10 mg (7.5 mg in patients with reduced kidney function) or placebo at the time of hospital discharge. The primary efficacy outcome was symptomatic VTE and VTE-related death. The principal safety outcome was major bleeding.
The final analysis included 12,019 patients, of whom 11,962 (99.5%) had taken at least one dose of study drug. The average age was 69.7 years and 48% were female. Four in ten patients had been admitted to hospital for heart failure, 27% for respiratory insufficiency, 17% for infectious disease, 14% for ischaemic stroke, and 2% for inflammatory disease.
During the 45-days post-discharge, 50 (0.83%) patients taking rivaroxaban had symptomatic VTE or died from VTE-related causes compared to 66 (1.1%) taking placebo (p=0.136). When examining symptomatic VTE only, which included lower extremity DVT and non-fatal pulmonary embolism, there were fewer events with rivaroxaban (0.18%) compared to placebo (0.42%; hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.22-0.89, p=0.023).
The researchers also examined an exploratory secondary composite endpoint of symptomatic VTE and all-cause mortality and found that 1.3% of patients taking rivaroxaban experienced an event compared to 1.78% of patients in the placebo group (HR 0.73, 95% CI 0.54-0.97, p=0.033).
Major bleeding occurred in 17 (0.28%) patients in the rivaroxaban group compared to nine (0.15%) taking placebo (p=0.124), with very few critical and fatal bleeds and no significant difference between groups.
Notes to editors
SOURCES OF FUNDING: Janssen R&D LLC.
DISCLOSURES: Consultant – Janssen.
References and notes
1 “MARINER – Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk” will be discussed during:
- Press Conference – Hot Line – Late Breaking Clinical Trials 1 on Sunday 26 August at 08:00 CEST.
- Hot Line Session 1 on Sunday 26 August at 14:30 to 15:45 CEST in the Munich Auditorium.
- Meet the Trialist – MARINER on Sunday 26 August at 15:55 to 16:15 CEST on the ESC TV Stage in ESC Plaza.
2 MARINER: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
About ESC Congress 2018
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2018 takes place 25 to 29 August at the Messe München in Munich, Germany. Explore the scientific programme.
More information is available from the ESC Press Office at [email protected]